Royal Bank of Canada Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $250.00

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) had its price target lifted by Royal Bank of Canada from $225.00 to $250.00 in a research note issued to investors on Tuesday, The Fly reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on ALNY. Citigroup raised their price target on Alnylam Pharmaceuticals from $206.00 to $280.00 in a research report on Thursday, August 4th. Evercore ISI lifted their price target on Alnylam Pharmaceuticals to $252.00 in a research report on Tuesday, August 9th. William Blair began coverage on Alnylam Pharmaceuticals in a research note on Tuesday, June 7th. They set an outperform rating for the company. SVB Leerink boosted their price target on Alnylam Pharmaceuticals from $96.00 to $98.00 and gave the stock a market perform rating in a research note on Wednesday, June 15th. Finally, Cantor Fitzgerald started coverage on Alnylam Pharmaceuticals in a report on Tuesday, July 12th. They set a neutral rating and a $175.00 price target for the company. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of Moderate Buy and a consensus price target of $232.06.

Alnylam Pharmaceuticals Trading Down 1.8 %

NASDAQ ALNY opened at $212.01 on Tuesday. The firm has a market capitalization of $25.45 billion, a P/E ratio of -25.95 and a beta of 0.58. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 3.85. The business has a fifty day simple moving average of $194.62 and a 200 day simple moving average of $163.58. Alnylam Pharmaceuticals has a 12 month low of $117.58 and a 12 month high of $236.80.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.67). The firm had revenue of $224.80 million for the quarter, compared to the consensus estimate of $256.06 million. Alnylam Pharmaceuticals had a negative return on equity of 204.18% and a negative net margin of 110.91%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.61) EPS. On average, analysts predict that Alnylam Pharmaceuticals will post -8.13 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Tolga Tanguler sold 1,754 shares of the firm’s stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $210.00, for a total transaction of $368,340.00. Following the transaction, the executive vice president now owns 3,629 shares of the company’s stock, valued at $762,090. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders have sold 5,349 shares of company stock valued at $1,033,073. 1.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. IndexIQ Advisors LLC grew its stake in Alnylam Pharmaceuticals by 21.5% in the 1st quarter. IndexIQ Advisors LLC now owns 2,413 shares of the biopharmaceutical company’s stock worth $394,000 after acquiring an additional 427 shares during the period. Cetera Advisor Networks LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 44.0% during the 1st quarter. Cetera Advisor Networks LLC now owns 4,299 shares of the biopharmaceutical company’s stock valued at $702,000 after acquiring an additional 1,313 shares in the last quarter. Gateway Investment Advisers LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 474.4% during the 1st quarter. Gateway Investment Advisers LLC now owns 26,239 shares of the biopharmaceutical company’s stock valued at $4,285,000 after acquiring an additional 21,671 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Alnylam Pharmaceuticals by 14.7% during the 1st quarter. Swiss National Bank now owns 518,010 shares of the biopharmaceutical company’s stock valued at $84,586,000 after acquiring an additional 66,300 shares in the last quarter. Finally, Bank of Montreal Can lifted its holdings in shares of Alnylam Pharmaceuticals by 86.8% during the 1st quarter. Bank of Montreal Can now owns 73,751 shares of the biopharmaceutical company’s stock valued at $12,433,000 after acquiring an additional 34,267 shares in the last quarter. 93.21% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

See Also

The Fly logo

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.